Daniel Faga (L) and Joseph Leveque (Mirati)

Weeks in­to CEO shake­up, Mi­rati bids adieu to a pair of C-suit­ers with KRAS drug fil­ing around the cor­ner

Mi­rati is on the cusp of emerg­ing as the sole chal­lenger against Am­gen in the sud­den­ly hot KRAS in­hibitor mar­ket and thinks it has the man to take it across the fin­ish line. But new lead­er­ship of­ten means shake­ups, and now two Mi­rati ex­ecs are be­ing shown the door.

Mi­rati CMO Joseph Lev­eque and Daniel Fa­ga, the biotech’s chief op­er­at­ing of­fi­cer and prin­ci­pal fi­nan­cial of­fi­cer, have both de­part­ed the com­pa­ny as it en­ters the home­stretch for fil­ing its KRAS drug ada­gra­sib with the FDA, Mi­rati re­vealed in an SEC fil­ing Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.